ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Gets Price Target Reduction from Oppenheimer

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price target lowered by equities researchers at Oppenheimer from $23.00 to $21.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. Oppenheimer‘s price objective suggests a potential upside of 14.63% from the company’s current price.

Several other equities research analysts have also recently commented on ACAD. Citigroup reissued a “buy” rating and set a $33.00 price target (down from $40.00) on shares of ACADIA Pharmaceuticals in a research report on Friday, September 25th. Deutsche Bank reduced their price objective on shares of ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, September 25th. Weiss Ratings restated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a report on Tuesday, November 10th. Bank of America reaffirmed a “buy” rating and issued a $14.50 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Finally, Citizens Jmp lowered their target price on ACADIA Pharmaceuticals from $36.00 to $33.00 and set a “market outperform” rating on the stock in a research report on Friday, September 25th. Thirteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.13.

Read Our Latest Analysis on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Stock Down 1.9%

Shares of ACAD stock opened at $18.32 on Wednesday. The company’s fifty day simple moving average is $21.41 and its 200-day simple moving average is $23.30. The firm has a market cap of $3.17 billion, a PE ratio of 8.68 and a beta of 0.87. ACADIA Pharmaceuticals has a 12 month low of $15.85 and a 12 month high of $30.96.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.20 by $0.11. The business had revenue of $342.30 million during the quarter, compared to analysts’ expectations of $332.58 million. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 8.90%. The firm’s revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.42 earnings per share. On average, equities analysts predict that ACADIA Pharmaceuticals will post 0.76 earnings per share for the current fiscal year.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Mark Schneyer sold 3,321 shares of the business’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the transaction, the executive vice president directly owned 71,322 shares in the company, valued at $1,489,203.36. The trade was a 4.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 26.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Algert Global LLC bought a new stake in ACADIA Pharmaceuticals in the 3rd quarter valued at $2,073,000. Virtu Financial LLC bought a new position in ACADIA Pharmaceuticals during the 3rd quarter worth $296,000. Krensavage Asset Management LLC bought a new position in ACADIA Pharmaceuticals during the 3rd quarter worth $806,000. Goldman Sachs Group Inc. increased its position in ACADIA Pharmaceuticals by 79.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 4,621,932 shares of the biopharmaceutical company’s stock worth $93,132,000 after buying an additional 2,041,817 shares during the period. Finally, Cetera Investment Advisers increased its position in ACADIA Pharmaceuticals by 9.1% during the 3rd quarter. Cetera Investment Advisers now owns 26,146 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 2,188 shares during the period. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

(Get Free Report)

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.

Further Reading

Analyst Recommendations for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.